GlassScriptPhysician profile
Dana E Hughes
NPI 1679963607
$8,295.00
in general payments reported to CMS, 2019-2025
41 companies · $2,107 in 2025
The $2,107 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,551 · 2022: $1,563 · 2023: $1,511 · 2024: $1,562 · 2025: $2,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,180.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,583.33 | 2021-2025 | |
| Pfizer INC. | $843.05 | 2021-2025 | |
| Novo Nordisk INC | $835.95 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $588.32 | 2021-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $577.99 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $539.77 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $527.24 | 2021-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $459.99 | 2021-2025 | |
| Glaxosmithkline, LLC. | $381.14 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $319.90 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.29 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $139.37 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $136.63 | 2021-2024 | Verquvo, Gardasil 9, Gardasil |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $133.18 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $128.27 | 2024-2025 | Rexulti |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $100.59 | 2024-2025 | Fanapt, Hetlioz |
| Amarin Pharma, INC. | $67.22 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $64.60 | 2023-2024 | Quviviq |
| Dynavax Technologies Corporation | $59.76 | 2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $57.71 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $54.80 | 2021-2023 | Seglentis, Livalo |
| Biogen, INC. | $47.84 | 2025 | Zurzuvae |
| Sanofi-Aventis U.S. LLC | $43.08 | 2022-2023 | |
| Exact Sciences Corporation | $40.69 | 2023-2024 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $40.44 | 2022-2023 | Qelbree |
| Tris Pharma INC | $35.54 | 2023 | Dyanavel Xr |
| Abbott Laboratories | $32.00 | 2022-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $31.57 | 2021-2024 | Trintellix |
| Radius Health, INC. | $30.81 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.76 | 2024 | Spravato |
| Eisai INC. | $27.73 | 2021 | |
| Sumitomo Pharma America, INC. | $25.16 | 2023 | Aptiom |
| Ardelyx, INC. | $24.44 | 2024 | Ibsrela |
| Neuronetics, INC. | $23.19 | 2025 | Neurostar Tms Therapy System |
| Axsome Therapeutics, INC. | $22.65 | 2024 | Auvelity |
| Neurelis, INC. | $21.30 | 2024 | Valtoco |
| Inspire Medical Systems, INC. | $17.64 | 2024 | Inspire |
| Scynexis, INC. | $15.60 | 2022 | |
| Astellas Pharma US INC | $14.97 | 2025 | Veozah |
| Ucb, INC. | $14.77 | 2023 | Briviact |
| Nevro Corp. | $12.72 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.